AIM Announces New Partnership With The Society for Immunotherapy of Cancer (SITC)

AIM at Melanoma is proud to announce our new online educational partnership with the Society for Immunotherapy of Cancer (SITC).  With the rapidly expanding cancer immunotherapy field, SITC created an online community, SITC Cancer Immunotherapy CONNECT (SITC CONNECT), to educate all who want to learn more about cancer immunotherapy. This active community of researchers, physicians, nurses, allied health professionals, industry personnel, and patients serves as the gateway for accessing current information on cancer immunotherapy.

With this new partnership, visitors to SITC CONNECT can now access many of AIM at Melanoma’s resources in the SITC Resource Library.

For more information about SITC or to create a free SITC CONNECT account, visit sitcancer.org.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on TwitterLinkedInFacebook and YouTube.

 

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

  • This field is for validation purposes and should be left unchanged.